Granted Patent
B2
US 12,551,490 · App. 18/150,117 · Granted Feb 17, 2026
Heterocyclic modulators of lipid synthesis
Inventors:
Douglas I. Buckley (San Mateo, CA); Gregory Duke (San Mateo, CA); Allan S. Wagman (San Mateo, CA); Marc Evanchik (San Jose, CA); Robert S. Mcdowell (San Francisco, CA)
Assignee:
Sagimet Biosciences Inc.
A61K31/55A61K31/437A61K31/451A61K31/4525A61K31/453A61K31/454A61K31/4545A61K31/496A61K31/501A61K31/506A61K31/5377C07D401/04C07D401/06C07D401/10C07D401/12C07D401/14C07D405/04C07D405/10C07D405/12C07D405/14C07D413/10C07D413/14C07D471/04C07D487/04C07D491/048C07D491/052C07D491/10C07D491/107C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatopepatitis (NASH).
Claims (15)
1 . A compound having Structure (XI):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H, —CN, halogen, C 1 -C 4 straight or branched alkyl, —O-(C 3 -C 8 cycloalkyl), or —O-(C 1 -C 4 straight or branched alkyl), wherein:
the C 3 -C 8 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and
when R 1 is not H, —CN or halogen, it is optionally substituted with one or more halogens;
each R 2 is independently H, halogen or C 1 -C 4 straight or branched alkyl;
R 3 is H, —OH, or halogen;
R 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl;
R 22 is H, halogen, C 1 -C 2 alkyl; and
R 351 is C 1 -C 2 alkyl or C 2 —O-(C 1 or C 2 alkyl).
2 . The compound of claim 1 , wherein R 3 is H or halogen.
3 . The compound of claim 1 , wherein R 21 is cyclobutyl.
4 . The compound of claim 1 , wherein R 1 is —CN.
5 . The compound of claim 1 , wherein R 22 is methyl.
6 . The compound of claim 1 , having a formula selected from the group consisting of:
Assignments (2)
CHANGE OF NAME
Recorded Apr 4, 2023
From: 3-V BIOSCIENCES, INC.
To: SAGIMET BIOSCIENCES INC.
Reel/Frame 063255/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 16, 2023
From: BUCKLEY, DOUGLAS; DUKE, GREGORY; WAGMAN, ALLAN S.; EVANCHIK, MARC; MCDOWELL, ROBERT S.
To: 3-V BIOSCIENCES, INC.
Reel/Frame 063003/0062 →
Continuity (19)
Continuation In Part
14874961
Continuation
PCTUS2013048950
· Jul 1, 2013
Provisional Application
61924520
· Jan 7, 2014
Provisional Application
61785933
· Mar 14, 2013
Provisional Application
61699819
· Sep 11, 2012
Provisional Application
61698511
· Sep 7, 2012
Provisional Application
61667894
· Jul 3, 2012
Provisional Application
61585642
· Jan 11, 2012
Provisional Application
61508611
· Jul 16, 2011
Provisional Application
61450561
· Mar 8, 2011
References Cited (143)
US 5759837A
· Kuhajda et al.
· 1998
[cited by applicant]
US 8871790B2
· Oslob et al.
· 2014
[cited by applicant]
US 9428502B2
· Oslob et al.
· 2016
[cited by applicant]
US 9624173B2
· Oslob et al.
· 2017
[cited by applicant]
US 9809591B2
· Oslob et al.
· 2017
[cited by applicant]
US 9994550B2
· Wagman et al.
· 2018
[cited by applicant]
US 20090105305A1
· Butlin et al.
· 2009
[cited by applicant]
US 20090118332A1
· Butlin et al.
· 2009
[cited by applicant]
US 20140322355A1
· Oslob et al.
· 2014
[cited by applicant]
US 20150099730A1
· Connolly
· 2015
[cited by applicant]
US 20170119786A1
· Buckley et al.
· 2017
[cited by applicant]
US 20190269694A1
· Buckley et al.
· 2019
[cited by applicant]
US 20220340556A1
· Buckley et al.
· 2022
[cited by applicant]
BR 112015000106A2
· 2017
[cited by applicant]
CN 101534836A
· 2009
[cited by applicant]
CN 105001225A
· 2015
[cited by applicant]
CN 106103425A
· 2016
[cited by applicant]
EP 1427421A1
· 2004
[cited by applicant]
JP 2009517438A
· 2009
[cited by applicant]
JP 2010502731A
· 2010
[cited by applicant]
MX 364815B
· 2019
[cited by applicant]
WO 2003033486A1
· 2003
[cited by applicant]
WO 2007052843A1
· 2007
[cited by applicant]
WO 2007063012A1
· 2007
[cited by applicant]
WO 2008030891A2
· 2008
[cited by applicant]
WO 2008059214A1
· 2008
[cited by applicant]
WO 2008075064A1
· 2008
[cited by applicant]
WO 2008075070A1
· 2008
[cited by applicant]
WO 2008075077A1
· 2008
[cited by applicant]
WO 2011043817A1
· 2011
[cited by applicant]
WO 2012122391A1
· 2012
[cited by applicant]
WO 2014008197A1
· 2014
[cited by applicant]
WO 2014039769A1
· 2014
[cited by applicant]
WO 2015084606A1
· 2015
[cited by applicant]
WO 2015095767A1
· 2015
[cited by applicant]
WO 2015105860A1
· 2015
[cited by applicant]
WO 2016025816A1
· 2016
[cited by applicant]
WO 2016149271A1
· 2016
[cited by applicant]
WO 2018089904A1
· 2018
[cited by applicant]
“Fatty Liver Disease”, WebMD [database online] 2017.1-6. [retrieved on May 3, 2017].
[cited by applicant]
“Interleukin 1 beta”, Wikipedia [database online]. 2017. 1-6 [retrieved on Mar. 3, 2024].
[cited by applicant]
“Metabolic syndrome”, Wikipedia [database online] 2017.1-15 [retrieved on May 3, 2017].
[cited by applicant]
Acton, Q. Ashton, “Multiple Myeloma: New Insights for the Healthcare Professional”, 2013 Edition, p. 71.
[cited by applicant]
Adams et al., “Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases”, Gut 2017, 66, pp. 1138-1153.
[cited by applicant]
Alisi et al., “The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications”, Mediators of Inflammation 2017, 2017, 15 pages.
[cited by applicant]
Alkhouri, N. et al. “Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD”, Gastroenterol Hepatol (NY); 8(10):661-8. (Oct. 2012).
[cited by applicant]
Appel et al. “Combination Therapy”, http.//www.healthcommunities.com/high-blood-pressure/combination-therapylhmwp.shtml, 2013, 1 paqe.
[cited by applicant]
Bentzien et al., “Pyrrolidinyl and piperidinyl compounds useful as NHE-1 inhibitors and their preparation and pharmaceutical compositions,” CAPLUS 152:144485, 2010.
[cited by applicant]
Bettermann et al., “Steatosis and Steatohepatitis: Complex Disorders”, International Journal of Molecular Sciences 2014, 15, p. 9924-9944.
[cited by applicant]
Browne, C.D., et al., “Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor”, (2006) FASEB J, 20(12):2027-2035.
[cited by applicant]
Byrne et al., “NAFLD: A multisystem disease”, Journal of Hepatology 2015, 62, p. S47-S64.
[cited by applicant]
Chakra Varthy, M.V., et al. ““New” hepatic fat activates PPARa to maintain glucose, lipid, and cholesterol homeostasis”, (2005) Cell Me tab. 1 :309-322.
[cited by applicant]
Colombo et al., “Novel Platforms for Oral Drug Delivery”, Pharmaceutical Research (2009), 26(3):601-611.
[cited by applicant]
Cui, “Preparation of aminoheteroaryl compounds as protein kinase inhibitors,” CAPLUS 141 :260769, 2004.
[cited by applicant]
EP Extended European Search Report for EP12754969, dated Sep. 3, 2014 (6 pages).
[cited by applicant]
Final—OA—14874961_Apr. 11, 2017 (12 Pages).
[cited by applicant]
Final—OA—15110154—Dec. 20, 2017 (6 Pages).
[cited by applicant]
Final—OA—15349960—Apr. 17, 2018 (12 Pages).
[cited by applicant]
First Examination Report for NZ Application No. 614879, dated May 20, 2014 (2 pages).
[cited by applicant]
Flavin, R., et al., “Fatty acid synthase as a potential therapeutic target in cancer”, (2010) Future Oneal., 6 (4):551-562.
[cited by applicant]
Furrer, “The central role of excipients in drug formulation”, European Pharmaceutical Review, Issue 2, 2013, downloaded from https://www.europeanpharmaceuticalreview.com/article/18434/the-central-role-of-excipients-in-d…
[cited by applicant]
Improper Markush, Fed. Reg. v.76(27) p. 7162-7175, slide 1, 64-67 (2011).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2012/028309, mailed Sep. 19, 2013 (7 pages).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2013/048950, dated Jan. 6, 2015 (11 pages).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2015/010459, mailed Jul. 12, 2016 (8 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/US2013/048950, mailed Oct. 29, 2013 (17 paqes).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2012/028309, mailed Jul. 13, 2012 (10 pages).
[cited by applicant]
Knust et al., “Preparation of piperidine derivatives as NK-3 receptor antagonists,” CAPLUS 153:456481, 2010.
[cited by applicant]
Lomonaco et al., “An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)”, Therapeutic Advances in Endocrinology and Metabolism 2011, 2(5), p. 211-225.
[cited by applicant]
Maier T. et al., “The Crystal Structure of a Mammalian Fatty Acid Synthase,” Science, vol. 321, 2008, pp. 1315-1322.
[cited by applicant]
Menet et al., “Novel triazolopyridine compounds as JAK kinase inhibitors useful for the treatement of degenerative and inflammatory diseases and their preparation,” CAPLUS 152:192130, 2010.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/415,660, dated of Dec. 24, 2013 (7 pages).
[cited by applicant]
Non-Final—OA—14315133_Jun. 4, 2015 (7 Pages).
[cited by applicant]
Non-Final—OA—14587908—Oct. 28, 2015 (19 Pages).
[cited by applicant]
Non-Final—OA—14874961_Sep. 16, 2016 (8 Pages).
[cited by applicant]
Non-Final—OA—15110154—Aug. 2, 2017 (11 Pages).
[cited by applicant]
Non-Final—OA—15201824—Mar. 28, 2017 (16 Pages).
[cited by applicant]
Non-Final—OA—15201824—Jul. 21, 2017 (10 Pages).
[cited by applicant]
Non-Final—OA—15349960—Jul. 21, 2017 (12 Pages).
[cited by applicant]
Non-Final—OA—16157672—Oct. 3, 2019 (10 Pages).
[cited by applicant]
Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/415,660, dated Apr. 9, 2014 (8 pages).
[cited by applicant]
Notice_of_Allowance—14874961—Jun. 29, 2017 (9 Pages).
[cited by applicant]
Notice_of_Allowance—15110154—Mar. 28, 2018 (8 Pages).
[cited by applicant]
Notice_of_Allowance—15201824—Jan. 17, 2018 (13 Pages).
[cited by applicant]
Notice_of_Allowance—16838753_May 10, 2022 (8 Pages).
[cited by applicant]
Notice_of_Allowance—Corrected—15201824—Feb. 12, 2018 (4 Pages).
[cited by applicant]
Notice_of_Allowance—Corrected—15201824—Apr. 2, 2018 (4 Pages).
[cited by applicant]
Notification of the First Office Action, for CN Application No. 201280020832.9, dated Jun. 9, 2014 (6 pages).
[cited by applicant]
Official Action for EA Aoolication No. 201391290, rec'd Oct. 17, 2014 (with English translation (5 pages).
[cited by applicant]
Orita, R. et al., “Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment”, (2007) Clin. Cancer Res., 13 (23):7139-7145.
[cited by applicant]
Patent Examination Report No. 1, for AU Application No. 2012225390, dated Oct. 6, 2014 (6 pages).
[cited by applicant]
Puig, T. et al., “A novel Inhibitor of fatty acid synthase shmvs activity against HER2+ breast cancer xenografts and is active in anti-HER.2 drug-resistant cell lines”, (2011) Breast Cancer Res., 13(6):R131 . . . .
[cited by applicant]
Rodon et al., “Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside”, The Oncologist (2010), 15:37-50.
[cited by applicant]
Sanders et al., “De nova lipogenesis in the liver in health and disease: more than just a shunting yard for glucose”, Biological Reviews 2016, 91, p. 452-468.
[cited by applicant]
Schneider et al., “Preparation of 5-alkynyl-pyrimidines as kinase inhibitors,” CAPLUS 155:271283, 2011.
[cited by applicant]
Steatosis. (n.d.) Segen's Medical Dictionary. (2011). Retreived Apr. 10, 2018 from https://medical-dictionary.thefreedictionary.com/steatosis.
[cited by applicant]
Wallenius, K. et al. “A Novel Fatty Acid Synthase Inhibitor Suppresses De Novo Lipogenesis but induces Hepatic Steatosis, Dermatitis and does not enhance Insulin Sensitivity in Obese Zucker Rats”, Conference: American D…
[cited by applicant]
Wu, M. et al., “Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes”, (2011) PNAS 108(13):5378-5383.
[cited by applicant]
Zhang et al., “Nonalcoholic Fatty liver Disease: Dyslipidemia,. Risk for Cardiovascular Complications, and Treatment Strategy”, Journal of Clinical Translational Hepatology 2015, 3, p. 78-84.
[cited by applicant]
“IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry”, Pure Appl. Chem., vol. 45, 1976, pp. 13-30.
[cited by applicant]
Bae, J. C.: “Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes”, Diabetes Care, vol. 34, 2011, pp. 727-729.
[cited by applicant]
Bertot et al. “The Natural course of Non-alcoholic fatty liver disease,” International J. Molecular Sciences, May 2016, 17, 774: doi: 10.3390/ijms17050774. (Year: 2016).
[cited by applicant]
Cordero et al., “Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet”, May 2012.
[cited by applicant]
Donnelly, K. L: “Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease”, 1. Cull. Invest., vol. 115, No. 5, 2005, pp. 1343-1351.
[cited by applicant]
Dorn et al. (Mar. 25, 2010) “Expression of Fatty Acid Synthase in Nonalcoholic Fatty Liver Disease”, International Journal of Clinical and Experimental Pathology, 3(5):505-514.
[cited by applicant]
Gerber K; Wimmer E; Paul AV, “Biochemical and Genetic Studies of the Initiation of Human Rhinovirus 2 RNA Replication: Identification of a cis-Replicating Element in the Coding Sequence of 2Apro”, J Virol, vol. 75, No. …
[cited by applicant]
Hardie DG, “Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase ”, Biochim. Biophys. Acta, vol. 1123, 1992, pp. 231-238.
[cited by applicant]
Huang H et al., “Structure of an RNA Hairpin from HRV-14 ”, Biochemistry, vol. 40, No. 27, 2001, pp. 8055-8064.
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2017/061330, mailed May 14, 2019 (8 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2017/0061330, mailed Jan. 29, 2018 (11 pages).
[cited by applicant]
Jensen-Urstad et al. (May 2012) “Fatty Acid Synthase and Liver Triglyceride Metabolism: Housekeeper or Messenger?”, Biochimica et Biophysica Acta, 1821(5):747-753.
[cited by applicant]
Kakazu, E. et al.: “Hepatocytes Release Ceramide-rich Proinflammatory Extracellular Vesicles in an IRElalpha dependent manner”, AASLD—The Liver Meeting, Nov. 13, 2015 (Nov. 13, 2015).
[cited by applicant]
Lambert, J. E: “Increased De Novo Lipogenesis is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease”, YGAST, vol. 146, No. 3, 2014, pp. 726-735.
[cited by applicant]
Lee, Y.: “Unexpected targets and triggers of autoimmunity”, J. Clin. Immunol., vol. 34, No. 1, 2014, pp. 56-60.
[cited by applicant]
Park S H et al., J. Appl. Physiol., vol. 92, 2002, pp. 2475-2482.
[cited by applicant]
Paul Av et al., Nature, “Protein-primed RNA synthesis by purified poliovirus RNA polymerase ”, vol. 393, No. 6682, 1998, pp. 280-284.
[cited by applicant]
Proud D et al., Am Jrespircrit Care Ivied, vol. 178, 2008, pp. 962-968.
[cited by applicant]
Roncari, “Mammalian Fatty Acid Synthetase. I. Purification and Properties of Human Liver Complex”, Can. J. Biochem., vol. 52, 1974, pp. 221-230.
[cited by applicant]
Rossmann M et al., “Structure of a human common cold virus and functional relationship to other picornaviruses ”, Nature, vol. 317, No. 6033, 1985, pp. 145-153.
[cited by applicant]
Sanders, Francis W. B.: “De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose”, Biol. Rev., vol. 91, 2016, pp. 452-468.
[cited by applicant]
Smith T et al., Science, vol. 233, No. 4770, 1986, pp. 1286-1293.
[cited by applicant]
Thompson et al., “Biosynthesis of Fatty Acids by Lactating Human Breast Epithelial Cells: An Evaluation of the Contribution to the Overall Composition of Human Milk Fat”, Pediatr. Res., vol. 19, 1985, pp. 139-143.
[cited by applicant]
Wei, Y.: “Saturated Fatty Acids Induce Endoplasmic Reticulum Stress and Apoptosis Independently of Ceramide in Liver Cells”, Am. J. Physio. Endocrinol. Metab., vol. 291, No. 2, 2006, pp. E275-E281.
[cited by applicant]
Yang, W. et al., “Fatty Acid Synthase is Upregulated during HCV Infection and Regulates HCV Entry and Production” Hepatology, vol. 48, No. 5, 2008, pp. 1396-1403.
[cited by applicant]